Cargando…

The level of fibroblast growth factor-2 prepared from Advanced Platelet Rich Fibrin (A-PRF) in obese Saudi subjects compared to healthy subjects

BACKGROUND: The prevalence of obesity has increased substantially in the last few decades. World Health Organization (2020) estimated that around 600 million obese adults worldwide were obese, and a further increase is expected in the future due to increased consumption of high-calorie diets and a s...

Descripción completa

Detalles Bibliográficos
Autores principales: AL KHATEEB, RANA MARWAN, TAWFIG, AHMED, ALMUGEIREN, OSAMA M., ALSAADOUN, NOUF H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pacini Editore Srl 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283641/
https://www.ncbi.nlm.nih.gov/pubmed/34322635
http://dx.doi.org/10.15167/2421-4248/jpmh2021.62.1.1632
Descripción
Sumario:BACKGROUND: The prevalence of obesity has increased substantially in the last few decades. World Health Organization (2020) estimated that around 600 million obese adults worldwide were obese, and a further increase is expected in the future due to increased consumption of high-calorie diets and a sedentary lifestyle as per the evidence. AIM: To evaluate and compare the level of fibroblast growth factor platelet rich fibrin (A-PRF) in obese subject compare to healthy weight subject. METHODS: Blood samples were collected from 23 volunteers, 15 obese subject (test group) and 8 non-obese (control group) at Riyadh Elm University. Considering the smaller sample size of our study, the results are to cautiously be interpreted for generalizability. Studies employing larger sample size are recommended to overcome this point. But considering the meticulous study procedure adhering to the study protocol and set criteria, the study pronounces greater internal validity in the sample chosen. The medical, dental histories, an interview and clinical examination was performed to check the eligibility of the participants to be involved in this study, Blood sample was collected in 10 ml syringe, then being processed using A-PRF centrifugation protocols. Ten milliliters of whole blood without anticoagulant was centrifuged at 1,300 rpm for 14 minutes. RESULTS: The level of FGF-2 released from (A-PRF) concentration was significantly lower on obese which was measured on 4 different times (day 1, day 7, day 14 and day 28), compared to healthy. CONCLUSIONS: There was decrease in FGF-2 level released from (A-PRF) from obese compared to healthy.